Latest Regulatory Progress News

Daly Resources has emerged from its June ASX debut with $11.05 million in cash, a 6,500 km² Northern Territory exploration portfolio and a growing list of drill targets. The catch is familiar for early-stage explorers: the company has yet to define a mineral resource or reserve, while its strongest Huckitta results remain surface sampling rather than drilling.

ReNerve’s October AGM presentation points to sharply higher sales, a growing US distribution network and a broader nerve repair pipeline. The company is also progressing a 240-patient NervAlign clinical study while relying on a $5 million RiverFort funding facility to support expansion.

Radiopharm Theranostics reported a A$56.3 million comprehensive loss for fiscal 2026, with operating cash outflows rising to A$52.8 million and cash falling to A$4.1 million. The company says further funding is required, while auditors flag a material uncertainty over its ability to continue as a going concern.

Titanium Sands has warned of material uncertainty over its ability to continue as a going concern, with just $112,578 in cash and $1.8 million of convertible notes due for repayment or conversion. The warning comes as the company prepares to submit the Environmental Impact Assessment for its Mannar Island mineral sands project in October.

Vectus Biosystems has secured a pre-IND Type B meeting with the FDA for its lead IPF drug candidate VB0004. The regulator’s written feedback, expected by mid-November, should clarify the next US development steps but does not yet authorise clinical trials.

D3 Energy has lifted its combined 2C recoverable helium resource by 65% to 35.6 BCF while securing A$6.12 million in fresh capital. The annual report also shows the cost of advancing the portfolio, with the FY2026 loss widening to A$6.11 million and operating cash outflow reaching A$3.84 million.

KALiNA Power returned to profit in FY2026 after booking A$19.6 million from the sale of a 180 MW Alberta load allocation linked to Meta. The company now has A$12.3 million in cash and four gas-fired power projects targeting about 900 MW, but future progress depends on fresh capital and project approvals.

Firebrick Pharma has received a $293,000 R&D Tax Incentive payment linked to $673,000 of eligible development spending on new Nasodine products. The non-dilutive cash arrives as the company broadens its product range and pursues approvals in additional markets.

Elementos has materially strengthened its balance sheet while moving its Spanish Oropesa tin project closer to permitting, financing and a final investment decision. The annual report also highlights a doubling of Cleveland’s inferred tungsten resource, but both projects still require substantial capital and further approvals.

EBR Systems’ new Santa Clara manufacturing facility has entered the FDA’s pre-approval inspection process, marking a key regulatory step for its wireless cardiac pacing business. The company continues to expect approval by the end of 2026, but the inspection does not yet amount to clearance.

Equus Energy has completed Pre-FEED on its large North West Shelf gas project and signed a conditional 10-year gas sales agreement with Alcoa. But the annual report also shows a $25 million loss, a $12 million rehabilitation provision and substantial funding and permitting hurdles before development can begin.

OncoSil Medical has secured $5.6 million from its three largest institutional investors to fund commercial launches of its OncoSil device in the United States and Australia. The commitments follow FDA and TGA approvals and would lift pro-forma cash to $12.1 million once completed.